Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC.ARWR · Entity 3472 | VP, Strategic Bus. Initiatives | October 19, 2018 | October 23, 2018 |
| BICYCLE THERAPEUTICS PLCBCYC · Entity 5993 | Chief Business Officer | May 28, 2019 | May 30, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARROWHEAD PHARMACEUTICALS, INC.
Report date October 19, 2018 · Filed October 23, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 160,000 |
Reported balance
After 2018-10-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-10-19 · Exercise / conversion · Acquired 30,000 · Balance 160,000 |
| Common StockSEC Table I · non-derivative | Direct | 194,375 |
Reported balance
After 2018-10-19 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2018-10-19 · Exercise / conversion · Acquired 34,375 · Balance 194,375 |
| Common StockSEC Table I · non-derivative | Direct | 261,137 |
Reported balance
After 2018-10-19 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2018-10-19 · Exercise / conversion · Acquired 66,762 · Balance 261,137 |
| Common StockSEC Table I · non-derivative | Direct | 130,000 |
Reported balance
After 2018-10-19 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2018-10-19 · Sale · Disposed 131,137 · Balance 130,000 F1: The price reported on Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.10 to $13.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.79 · Expires 2023-07-20 | Direct | 190,000 |
Reported balance
After 2018-10-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-10-19 · Exercise / conversion · Disposed 30,000 · Balance 190,000 F3: Represents first vesting date. Option vests over four years from date of grant. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $6.15 · Expires 2026-01-01 | Direct | 155,625 |
Reported balance
After 2018-10-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-10-19 · Exercise / conversion · Disposed 34,375 · Balance 155,625 F3: Represents first vesting date. Option vests over four years from date of grant. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $7.75 · Expires 2025-03-06 | Direct | 88,863 |
Reported balance
After 2018-10-19 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-10-19 · Exercise / conversion · Disposed 66,762 · Balance 88,863 F3: Represents first vesting date. Option vests over four years from date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported on Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.10 to $13.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.
F3: Represents first vesting date. Option vests over four years from date of grant.
BICYCLE THERAPEUTICS PLC
Report date May 28, 2019 · Filed May 30, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2029-05-28 | Direct | 43,269 |
Reported balance
After 2019-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-28 · Grant · Acquired 43,269 · Balance 43,269 F1: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2019 Filed May 30, 2019 21:25 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantStock Option (Right to Buy) · Derivative | 43,269 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001104659-19-032911 · a4.xml · derivative · entry 1 Leone Peter Brian · CIK 0001635893 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,269 Underlying: Ordinary Shares · 43,269 shares Expires 2029-05-28 F1 · derivative.exercise_date: This option shall vest in 36 equal monthly installments at the end of each calendar month following the date of the grant. Read SEC document |
| October 19, 2018 Filed Oct 23, 2018 23:59 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Options · Derivative | 66,762 | $0.00 Strike: $7.75 | $0.00 |
DisclosureSEC source: 0001209191-18-055999 · doc4.xml · derivative · entry 7 Leone Peter Brian · CIK 0001635893 · VP, Strategic Bus. Initiatives 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,863 Underlying: Common Stock · 66,762 shares Expires 2025-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents first vesting date. Option vests over four years from date of grant. Read SEC document |
| October 19, 2018 Filed Oct 23, 2018 23:59 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Options · Derivative | 34,375 | $0.00 Strike: $6.15 | $0.00 |
DisclosureSEC source: 0001209191-18-055999 · doc4.xml · derivative · entry 6 Leone Peter Brian · CIK 0001635893 · VP, Strategic Bus. Initiatives 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,625 Underlying: Common Stock · 34,375 shares Expires 2026-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents first vesting date. Option vests over four years from date of grant. Read SEC document |
| October 19, 2018 Filed Oct 23, 2018 23:59 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Options · Derivative | 30,000 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001209191-18-055999 · doc4.xml · derivative · entry 5 Leone Peter Brian · CIK 0001635893 · VP, Strategic Bus. Initiatives 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 30,000 shares Expires 2023-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents first vesting date. Option vests over four years from date of grant. Read SEC document |
| October 19, 2018 Filed Oct 23, 2018 23:59 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 131,137 | $13.49 | $1,769,038.13 |
DisclosureSEC source: 0001209191-18-055999 · doc4.xml · nonDerivative · entry 4 Leone Peter Brian · CIK 0001635893 · VP, Strategic Bus. Initiatives 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 F1 · price: The price reported on Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.10 to $13.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| October 19, 2018 Filed Oct 23, 2018 23:59 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 66,762 | $7.75 | $517,405.50 |
DisclosureSEC source: 0001209191-18-055999 · doc4.xml · nonDerivative · entry 3 Leone Peter Brian · CIK 0001635893 · VP, Strategic Bus. Initiatives 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 19, 2018 Filed Oct 23, 2018 23:59 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 34,375 | $6.15 | $211,406.25 |
DisclosureSEC source: 0001209191-18-055999 · doc4.xml · nonDerivative · entry 2 Leone Peter Brian · CIK 0001635893 · VP, Strategic Bus. Initiatives 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 19, 2018 Filed Oct 23, 2018 23:59 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 30,000 | $2.79 | $83,700.00 |
DisclosureSEC source: 0001209191-18-055999 · doc4.xml · nonDerivative · entry 1 Leone Peter Brian · CIK 0001635893 · VP, Strategic Bus. Initiatives 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 01, 2018 Filed Jan 4, 2018 00:36 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-001523 · doc4.xml · nonDerivative · entry 1 Leone Peter Brian · CIK 0001635893 · VP, Strategic Bus. Initiatives 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments. Read SEC document |
| January 01, 2017 Filed Jan 5, 2017 01:44 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-001617 · doc4.xml · nonDerivative · entry 1 Leone Peter Brian · CIK 0001635893 · VP, Strategy & Program Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment in January 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.